BRISBANE, 16 October 2014: Anatara Lifesciences is pleased to announce it has successfully listed on the Australian Securities Exchange (ASX) under the ticker code ANR.
The company raised $7 million in an oversubscribed offer with strong support from institutional and retail investors.
“This is an exciting day for Anatara as we take our first steps as a public company addressing an unmet need for effective non-antibiotic treatments and medicines,” Anatara Chairman and Co-Founder Dr Mel Bridges said.
Anatara’s lead product, DetachTM, is a non-antibiotic therapy to treat and prevent diarrhoea. The company is focused on commercialising DetachTM initially for use in pigs, ahead of expanding its use to other livestock, and then developing it for use in humans.
Health authorities around the world are moving to limit the use of antibiotics in animal production as their overuse contributes to the rise of antibiotic-resistant bacteria, so-called superbugs that threaten human health.
Anatara’s objectives include:
• Registration of DetachTM for use in pigs in Australia and the European Union
• Registration of DetachTM for use in pigs in the United States
• Development of DetachTM for humans
Dr Bridges thanked investors for taking part in Anatara’s IPO and embracing the company’s vision.
“We look forward to updating shareholders on our progress with DetachTM and seeing this important and innovative product enter the market,” he said.
The IPO was led by Wilson HTM with co-manager Peloton Capital and legal advisers McCullough Robertson.
For more information please contact:
General inquiries
Mel Bridges
Chairman
+61 (0) 413 051 600
melbridges@parmacorp.com
Media inquiries
Gavin Lower
Buchan Consulting
+61 3 8866 1215
glower@buchanwe.com.au
About Anatara Lifesciences
Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Help employers find you! Check out all the jobs and post your resume.
